Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients
A hard-charging group of Novartis execs have been pouring over the late-stage data they gathered to support their successful campaign to win an FDA approval for Mayzent (siponimod) as a landmark new therapy for multiple sclerosis. And it’s paid off
Crunching the data on their MS drug — tapped as a $1.3 billion blockbuster-in-the-making by Evaluate — researchers concluded that there was clear statistical evidence to show that their drug both preserved the cognitive powers of secondary progressive MS patients treated earlier in the course of their disease as well boosting the ability of patients to think. Patients on their drug beat a control group given a placebo.
Basic subscription required
Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.